Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays

Background: Denecimig (Mim8, Novo Nordisk A/S) is a next-generation bispecific antibody designed to mimic activated factor (F)VIII and restore hemostasis in persons with hemophilia A. The extent to which activated FVIII mimetics, such as denecimig and emicizumab, can correct clotting deficiency rema...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Jacob Lund, Mirella Ezban, Kasper Jensen, David Lillicrap
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2026-01-01
Schriftenreihe:	Research and Practice in Thrombosis and Haemostasis
Schlagworte:	bioequivalence bispecific antibodies factor VIII hemophilia thrombin
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2475037925006570
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!